Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026

Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held ...
Yahoo Finance

Cellectis to Report First Quarter Financial Results on May 11, 2026

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Yahoo Finance

Cellectis S.A. (0WA2.L) Q2 FY2025 earnings call transcript

Earnings call Cellectis ended Q2 2025 with $230 million in cash, sufficient to fund operations into H2 2027, down from $264 million at year-end 2024. The company is advancing UCART22 into pivotal ...
STAT

Cellectis off-the-shelf CAR-T therapy grounded following patient’s toxic death

Two clinical trials of an off-the-shelf CAR-T cancer therapy from Cellectis (CLLS) have been placed on clinical hold following the death of a patient caused by a severe toxic reaction to the treatment ...
Nasdaq

Cellectis and Servier Execute the Amendment Confirming the Expansion of Their Collaboration on UCART19 Products

Cellectis grants additional rights to Servier to develop and commercialize all next generation gene-edited allogeneic CAR T-cell products targeting CD19, including ALLO-501A NEW YORK--(BUSINESS WIRE)- ...
FiercePharma

Cellectis bioresearch Makes Genome Engineering Affordable for All Users

PARIS, Feb. 28, 2011 /PRNewswire/ -- Cellectis bioresearch, a specialist in genome customization and subsidiary of Cellectis (Alternext: ALCLS), has today launched TALEN Access™, the first ...

Cellectis S.A. Sponsored ADR

View Cellectis S.A. Sponsored ADR CLLS stock quote prices, financial information, real-time forecasts, and company news from CNN.
Nasdaq

Cellectis and Sanofi partner on alemtuzumab as lymphodepletion agent for allogeneic CAR-T

PARIS, May 11, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – Euronext Growth: ALCLS), a clinical-stage biotechnological company employing its core proprietary technologies to develop best-in ...
Reuters

AstraZeneca to invest $245 mln in Cellectis to boost gene therapy prospects

Nov 1 (Reuters) - AstraZeneca (AZN.L), opens new tab said on Wednesday it would invest $245 million in French biotechnology company Cellectis (ALCLS.PA), opens new tab in a deal aimed at speeding up ...
Business Insider

Cellectis Completes Sale of $47 million through its ATM program

NEW YORK, April 09, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a clinical-stage biotechnological company employing its core proprietary ...
Business Wire

Cellectis and Servier Execute the Amendment Confirming the Expansion of Their Collaboration on UCART19 Products

NEW YORK--(BUSINESS WIRE)--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing ...